Skip to content
naulon
Not checkedNot checked for notices yet.

Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR

F. Tudor Ilca, Linnea Z. Drexhage, Gemma Brewin and 2 more

Cell Reports · 2019

doi:10.1016/j.celrep.2019.09.074 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Summary: Understanding how peptide selection is controlled on different major histocompatibility complex class I (MHC I) molecules is pivotal for determining how variations in these proteins influence our predisposition to infectious diseases, cancer, and autoinflammatory conditions. Although the intracellular chaperone TAPBPR edits MHC I peptides, it is unclear which allotypes are subjected to TAPBPR-mediated peptide editing. Here, we examine the ability of 97 different human leukocyte antigen (HLA) class I allotypes to interact with TAPBPR. We reveal a striking preference of TAPBPR for HLA-A, particularly for supertypes A2 and A24, over HLA-B and -C molecules. We demonstrate that the increased propensity of these HLA-A molecules to undergo TAPBPR-mediated peptide editing is determined by molecular features of the HLA-A F pocket, specifically residues H114 and Y116. This work reveals that specific polymorphisms in MHC I strongly influence their susceptibility to chaperone-mediated peptide editing, which may play a significant role in disease predisposition.: Ilca et al. explore which human leukocyte antigen class I allotypes are subjected to TAPBPR-mediated peptide editing, revealing TAPBPR has preference for HLA-A, particularly for supertypes A2 and A24, over HLA-B and -C molecules. Keywords: MHC, HLA, polymorphism, TAPBPR/TAPBPL, antigen processing and presentation

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.